Please login to the form below

Not currently logged in
Email:
Password:

Novartis discontinues cancer trial

Novartis has discontinued a clinical trial programme for investigational cancer treatment ASA404, incurring impairment charges of $120m

Novartis has announced it has discontinued a clinical trial programme for investigational cancer treatment ASA404 (vadimezan) after interim results from a phase III study showed the drug was unlikely to meet its primary endpoint, failing to extend patient survival.

The decision to end the programme means the Swiss company will face impairment charges of $120m to be taken in the fourth quarter of 2010. An impairment charge is a decrease in the value of a company based on inflated previous estimates regarding a company's intangible assets.

Novartis has already been hit by impairment charges in 2010, with the company facing costs of $590m when it discontinued the development of investigational compounds Mycograb (efungumab) and albinterferon alfa-2b.

Research into ASA404 was halted following a recommendation from an independent data monitoring committee to end the phase III trial, ATTRACT-2, ahead of schedule.

The trial was designed to investigate if the treatment significantly extended overall survival in patients with advanced non-small cell lung cancer (NSCLC) when used in combination with chemotherapy.

ASA404 had previously failed to meet the primary endpoint of ATTRACT-1 trial. This study evaluated the drug in combination with paclitaxel and carboplatin as first-line treatment for advanced NSCLC.

11th November 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Dovetail

We're award-winning joint working specialists. We help our clients to transform healthcare through effective collaboration, and deliver work to feel...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics